We have determined the protein X-ray crystal structures of four organometallic inhibitors in complex with their target enzyme carbonic anhydrase II. The barrel shaped hydrophobic ferrocene and ruthenocene moieties have provided a structure-based avenue to better occupy the 10 hydrophobic binding patch within the enzyme active site.
3PYK
) 3 and a half-sandwich ruthenium complex with glycogen synthase kinase 3β (PDB ID 3M1S). 4 Metallocenes are organometallic compounds comprising a sandwich structure wherein the metal ion is located between two cyclopentadienyl (Cp) rings. The π-electrons from each Cp ring 25 are delocalised throughout the compound and this accounts for similar chemical behaviour of ferrocenes and ruthenocenes to that of aromatic compounds such as benzenes. The ferrocenyl moiety is air and water stable, non-toxic and its metabolism is compatible with in vivo applications. 5 There are numerous 30 ferrocene-based compounds reported with good drug-like properties 5a and several ferrocene-based compounds have found application in drug discovery, for example ferrocerone has been used to treat iron deficiency anaemia, 6 while hydroxyferrocifen (a Tamoxifen   TM analogue) 7 and ferroquine (a chloroquine 35 analogue) 8 are in clinical development for the treatment of breast cancer and malaria, respectively. Ruthenocene and its derivatives are much less studied than their isostructural ferrocene counterparts, and to date only a small number of ruthenocenebased compounds appear in the literature of drug discovery. At hCA II (h = human) the ferrocenyl 1,5-disubstituted triazole regioisomer 2 (K i = 36 nM) has 2-fold better CA II inhibition than the 1,4-disubstituted triazole regioisomer 1 (K i = 80 nM). [13] [14] The ruthenocene derivatives, with K i s of 9.7 nM (3) and 12 nM 75 (4) nM, share similar hCA II inhibition and are 3-to 8-fold better hCA II inhibitors than their ferrocene counterparts. Compounds 1-4 are closely related in structure and likely to experience similar desolvation energies on binding to CA II. We therefore propose that the variable interactions of the barrel shaped 80 hydrophobic metallocene moiety with the CA II protein may account for differences in inhibition to inform our understanding of structure-activity relationships and provide a structural base on which to direct future metallocene-based CA inhibitor design. To obtain insight into the triazole-metallocene tail group interactions with the CA active site amino acids we have utilised protein Xray crystallography to determine the crystal structures of human CA II in complex with inhibitors 1-4. The crystal structures of the CA-metallocene-based inhibitor complexes were determined to 2.0 Å resolution (CA II:1), 1. II:4). The binding mode of the sulfonamide moiety to the catalytic zinc ion is invariant as compared to other sulfonamidebound CA II structures. The metallocene-triazole tail groups of the inhibitors occupy space in the active site cavity of CA II without altering the configuration of residues lining the cavity. 15 The binding cavity of CA comprises a cone-shaped active site with a hydrophobic and a hydrophilic face. 10 The metallocenyl moieties are oriented towards the upper region of the hydrophobic face with both Cp rings involved in van der Waals interactions with residues constituting the hydrophobic face ( The ferrocenyl ligand of PDB ID 1A3L has substituents on both Cp rings that hydrogen bond to the antibody. Cp ring rotation 50 appears restricted to maximize the number of specific interactions of the substituents with the antibody. The electron density provides no suggestion of multiple conformations, with the antibody acting to trap one conformer. 2 In contrast, the unsubstituted Cp ring in compounds 1-4 of this study form only 55 hydrophobic interactions with the protein residues, such that a relatively unrestricted rotation of the unsubstituted Cp ring with respect to the substituted Cp ring is likely. This assumption is supported by the electron density observed in the crystal structures of CA II:1-4 which is less well defined for the 60 unsubstituted Cp ring than for the substituted Cp ring. The backbone of the 1,4-disubstituted-1,2,3-triazoles 1 and 3 adopts a near-linear topology, whereas the 1,5-disubstituted-1,2,3-triazoles 2 and 4 exhibit a corkscrew topology (Fig. 4) , a phenomenon which has previously been observed with 65 disubstituted 1,2,3-triazoles regioisomers. 16 Both bound conformations are hypothesised to constitute the lowest energy conformations of the ligands in solution such that the binding of metallocenes 1-4 to human CA II does not require significant bond rotations to accommodate the ligands. The shape complementarity of the ligands in their most favourable conformations with parts of the CA II active site, combined with the stable anchoring of the compounds to the active site zinc cation via the sulfonamide anion, are consistent with the good CA 5 II inhibition constants observed. As well the ruthenium cation is larger than the iron cation and this increases the Cp ring separation in the ruthenocenyl ligands 3 and 4 compared to 1 and 2. This more subtle structural variation may account for the observed difference in enzyme inhibition properties, with the 10 ruthenocenyl ligands 3 and 4 3-to 8-fold better CA II inhibitors than their ferrocenyl counterparts 1 and 2.
In conclusion, there are few reports in which an organometallic inhibitor has been complexed with its target protein and a crystal structure obtained. Herein we have utilised protein X-ray II in complex with two ferrocene-(1, 2) and two ruthenocenebased organometallic inhibitors (3, 4) , to 1. 
